Literature DB >> 16047716

Immediate hypersensitivity to quinolones: moxifloxacin cross-reactivity.

I González1, T Lobera, A Blasco, M D del Pozo.   

Abstract

INTRODUCTION: Immediate hypersensitivity reactions to quinolones are rare. Moxifloxacin is an quinolone chemically different from other fluoroquinolones. We report 6 patients diagnosed with hypersensitivity to different fluoroquinolones in whom the response to moxifloxacin and cross-reactivity with other quinolones was studied. MATERIAL-
METHODS: An allergenic study was made by prick and intradermal test with different fluoroquinolones, in all the patients. Single blind oral challenge tests were performed with moxifloxacin in all the patients, with ciprofloxacin in five patients, with levofloxacin in three patients and with ofloxacin in one patient.
RESULTS: The skin test performed with moxifloxacin was positive in five patients, and the oral challenge test was positive in all six patients. All the patients had at least one positive skin test with some of the other fluoroquinolones.
CONCLUSION: The skin test with different quinolones seems to be sensitive at showing group hypersensitivity, but not at predicting specific tolerance of each drug. We found a high degree of cross-reactivity among fluoroquinolones, so we currently recommend to avoid the group. We did not find that moxifloxacin differed from other fluoroquinolones so we cannot recommend it as a valid therapeutic alternative in patients sensitized to other quinolones.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16047716

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  13 in total

Review 1.  Antimicrobial stewardship's new weapon? A review of antibiotic allergy and pathways to 'de-labeling'.

Authors:  Jason Trubiano; Elizabeth Phillips
Journal:  Curr Opin Infect Dis       Date:  2013-12       Impact factor: 4.915

2.  Subacute cutaneous lupus erythematosus observed with ciprofloxacin.

Authors:  Andrew J Newman; Dustin Mullens; Christine C Lin; Jason Barr
Journal:  BMJ Case Rep       Date:  2018-12-22

Review 3.  Update on Quinolone Allergy.

Authors:  Inmaculada Doña; Esther Moreno; Natalia Pérez-Sánchez; Inmaculada Andreu; Dolores Hernández Fernandez de Rojas; María José Torres
Journal:  Curr Allergy Asthma Rep       Date:  2017-08       Impact factor: 4.806

4.  Update on the management of antibiotic allergy.

Authors:  Bernard Yu-Hor Thong
Journal:  Allergy Asthma Immunol Res       Date:  2010-03-24       Impact factor: 5.764

5.  US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactions.

Authors:  S Christopher Jones; Daniel S Budnitz; Alfred Sorbello; Hina Mehta
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-08-20       Impact factor: 2.890

6.  Cross sensitivity between ciprofloxacin and levofloxacin for an immediate hypersensitivity reaction.

Authors:  Ashish P Anovadiya; Manish J Barvaliya; Tejas K Patel; C B Tripathi
Journal:  J Pharmacol Pharmacother       Date:  2011-07

7.  Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy.

Authors:  Mario Sánchez-Borges; Bernard Thong; Miguel Blanca; Luis Felipe Chiaverini Ensina; Sandra González-Díaz; Paul A Greenberger; Edgardo Jares; Young-Koo Jee; Luciana Kase-Tanno; David Khan; Jung-Won Park; Werner Pichler; Antonino Romano; Maria José Torres Jaén
Journal:  World Allergy Organ J       Date:  2013-10-31       Impact factor: 4.084

8.  Moxifloxacin induced fatal hepatotoxicity in a 72-year-old man: a case report.

Authors:  Rajanshu Verma; Radhika Dhamija; Donald H Batts; Stephen C Ross; Mark E Loehrke
Journal:  Cases J       Date:  2009-07-20

9.  Immunologic evaluation of ofloxacin hypersensitivity.

Authors:  Young-Hee Nam; Jeong Eun Kim; Seung-Hyun Kim; Hyun Jung Jin; Eui-Kyung Hwang; Yoo Seob Shin; Young-Min Ye; Hae-Sim Park
Journal:  Allergy Asthma Immunol Res       Date:  2012-06-15       Impact factor: 5.764

10.  Hypersensitivity to fluoroquinolones: The expression of basophil activation markers depends on the clinical entity and the culprit fluoroquinolone.

Authors:  Tahia D Fernández; Adriana Ariza; Francisca Palomares; María I Montañez; María Salas; Angela Martín-Serrano; Rubén Fernández; Arturo Ruiz; Miguel Blanca; Cristobalina Mayorga; María J Torres
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.